Pasireotide (SOM230) as a Potential Treatment for Endocrine and Non- Endocrine Tumors

E-ISSN： 2212-3903|5|4|301-311

ISSN： 1574-8855

Source： Current Drug Therapy, Vol.5, Iss.4, 2010-11, pp. : 301-311

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Somatomedin-1 (Recombinant Insulin-Like Growth Factor-1): Clinical Pharmacology and Potential Treatment of Endocrine and Metabolic Disorders

By Laron Z.

BioDrugs, Vol. 11, Iss. 1, 1999-01 ,pp. : 55-70

Adis International

Access to resources Recommend Favorite

Cutaneous Manifestations of Endocrine Disorders: A Guide for Dermatologists

By Jabbour S.A.

American Journal of Clinical Dermatology, Vol. 4, Iss. 5, 2003-01 ,pp. : 315-331

Adis International

Access to resources Recommend Favorite

Asystole, rhabdomyolysis and acute renal failure as initial presentation of phaeochromocytoma in multiple endocrine neoplasia (MEN) type IIA

By KÖPPEL C SCHIROP T BARCKOW D FREI U

Clinical Intensive Care, Vol. 6, Iss. 5, 1995-10 ,pp. : 245-245

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Non-Melanocytic Benign Skin Tumors in Children

By Lucas Ana

American Journal of Clinical Dermatology, Vol. 8, Iss. 6, 2007-01 ,pp. : 365-369

Adis International

Access to resources Recommend Favorite

Effectiveness of low‐dose pasireotide in a patient with Cushing's disease: antiproliferative effect and predictivity of a short pasireotide suppression test

Clinical Case Reports, Vol. 3, Iss. 8, 2015-08 ,pp. : 718-722

John Wiley & Sons Inc

Access to resources Recommend Favorite